



YOUR GUIDE TO STARTING RYBREVANT®

RYBREVANT® can be given as a first treatment or a second treatment, alone or in combination with other treatments, depending on the type of EGFR+ non-small cell lung cancer (NSCLC)

EGFR+ = mutated epidermal growth factor receptor

What is RYBREVANT® (amivantamab-vmjw)?

RYBREVANT® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal epidermal growth factor receptor (EGFR) gene(s):

- in combination with LAZCLUZE™ (lazertinib), a prescription medicine, as a first-line treatment for non-small cell lung cancer (NSCLC)
- in combination with carboplatin and pemetrexed as a second-line treatment for NSCLC in patients whose disease has worsened on or after treatment with an EGFR tyrosine kinase inhibitor (TKI)
- in combination with carboplatin and pemetrexed as a first-line treatment for NSCLC
- alone for the treatment of NSCLC whose disease has worsened on or after platinum-based chemotherapy.

Your healthcare provider will perform a test to make sure that RYBREVANT® or RYBREVANT® in combination with LAZCLUZE™ is right for you.

It is not known if RYBREVANT® or LAZCLUZE™ is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Before you receive RYBREVANT® as a single agent or in combination, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of lung or breathing problems.
- are pregnant or plan to become pregnant. RYBREVANT® and LAZCLUZE™ can harm your unborn baby.

Please read Important Safety Information throughout and on pages 11-14.

Please read full [Prescribing Information](#) for RYBREVANT® and full [Prescribing Information](#) for LAZCLUZE™.

About Lung Cancer and *EGFR* Mutations

Lung cancer

Lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. As these cells grow, they form tumors. When cells from tumors spread to other parts of the body, it's called "advanced" or "metastatic" cancer.



Non-small cell lung cancer

The 2 most common types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

The difference between these types of lung cancer is how the cancer cells look under a microscope. There may be different treatments approved for use for each type.

Your doctor diagnosed you with NSCLC, the most common type of lung cancer, making up about 80% to 85% of all cases.



Biomarker testing may help your doctor identify the appropriate treatment

A biomarker is any molecule that can help show when your body is working normally or abnormally. This includes mutations in certain cells associated with advanced NSCLC. A biomarker test identifies biomarkers by testing body tissue, blood, or other bodily fluids, and can help your doctor determine which treatment is best for you.

Testing showed that you have a certain *EGFR* mutation.

IMPORTANT SAFETY INFORMATION (cont'd)

Females who are able to become pregnant:

- o Your healthcare provider should do a pregnancy test before you start treatment with RYBREVANT[®] or RYBREVANT[®] in combination with LAZCLUZE[™].
- o You should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT[®].
- o For patients receiving LAZCLUZE[™]: You should use effective birth control (contraception) during treatment and for 3 weeks after your last dose of LAZCLUZE[™].
- o Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT[®] or LAZCLUZE[™].

Please read Important Safety Information throughout and on pages 11-14.

Please read full [Prescribing Information](#) for RYBREVANT[®] and full [Prescribing Information](#) for LAZCLUZE[™].

About Lung Cancer and *EGFR* Mutations (cont'd)



EGFR mutations

EGFR is a protein found on both normal cells and cancer cells. It drives cells to survive and grow. *EGFR* mutations may cause cancer cells to overgrow and spread to other parts of the body.

EGFR exon 19 deletions/exon 21 L858R mutations

There are 2 *EGFR* mutations that represent 80% to 90% of all *EGFR* mutations in NSCLC. These are called "exon 19 deletion" and "exon 21 L858R."

EGFR exon 20 insertion mutations

There are other, less common mutations. One kind of *EGFR* mutation is called an "exon 20 insertion" mutation. Exon 20 insertion mutations are the third most frequent *EGFR* mutation in NSCLC.

IMPORTANT SAFETY INFORMATION (cont'd)

Males who have female partners who are able to become pregnant:

- o You should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE[™].
- are breastfeeding or plan to breastfeed. It is not known if RYBREVANT[®] or LAZCLUZE[™] passes into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT[®] or RYBREVANT[®] in combination with LAZCLUZE[™].

Please read Important Safety Information throughout and on pages 11-14.

Please read full [Prescribing Information for RYBREVANT[®]](#) and full [Prescribing Information for LAZCLUZE[™]](#).

How RYBREVANT[®] Is Given

RYBREVANT[®] is an infusion given into your vein through an intravenous (IV) line

- You will receive RYBREVANT[®] at your doctor's office or an infusion center
- Your doctor will decide how many doses you will receive, the time between doses, and the appropriate dose of each RYBREVANT[®] infusion based on your body weight
- Your doctor will give you other medicines before each dose of RYBREVANT[®] to help reduce the risk of side effects. These medicines include allergy medicine, a fever reducer, and a steroid

RYBREVANT[®] may be given in combination with other medicines, depending on the type of NSCLC

For the first treatment of advanced NSCLC with *EGFR* mutations (exon 19 deletions or exon 21 L858R)

- RYBREVANT[®] is approved in combination with LAZCLUZE[™], a pill you can take once a day, on your own schedule. Take LAZCLUZE[™] exactly how your doctor tells you to
- When RYBREVANT[®] is given in combination with LAZCLUZE[™], your doctor will start you on medicine to prevent blood clots for the first 4 months of treatment

For the second treatment of advanced NSCLC with *EGFR* mutations (exon 19 deletions or exon 21 L858R) and for the first treatment of advanced NSCLC with *EGFR* exon 20 insertion mutations

- RYBREVANT[®] is approved with chemotherapy. Chemotherapy consists of carboplatin and pemetrexed, which are also infusions given into your vein through an IV line

IMPORTANT SAFETY INFORMATION (cont'd)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

LAZCLUZE[™] may affect the way other medicines work, and other medicines may affect how LAZCLUZE[™] works.

You should not start or stop any medicine before you talk with your healthcare provider that prescribed LAZCLUZE[™].

Please read Important Safety Information throughout and on pages 11-14.

Please read full [Prescribing Information](#) for RYBREVANT[®] and full [Prescribing Information](#) for LAZCLUZE[™].

Preparing for Treatment

Tips to help you prepare for your infusion appointment



Drink plenty of water the day before and have a good breakfast on infusion day.



Infusions can last several hours, so make sure you've set aside enough time for your appointment. Ask your care team about how long your infusion will be.



Ask the office if it's okay to **bring a drink and snack** with you in case you get hungry.



Consider setting up transportation to and from the infusion center. You may receive medicines before your infusion that can make you drowsy. If you need help setting up a ride, reach out to your family and friends.



Wear loose clothes for comfort and so your care team can easily reach the infusion area of your body.



Bring a pillow and blanket for extra comfort.



Bring a book, game, puzzle, music, or other entertainment to help pass the time.



Pay close attention to how you feel during an infusion, and make sure to let your care team know if you experience any discomfort. They know how to help.

If you have any other questions about your infusions, ask your care team

Please read Important Safety Information throughout and on pages 11-14.

Please read full [Prescribing Information](#) for RYBREVANT[®] and full [Prescribing Information](#) for LAZCLUZE[™].

Side Effects

Your care team will continuously support you along your treatment journey. It's important to tell your care team about side effects right away, if you:

- First experience symptoms of side effects
- Feel that the side effects are affecting daily activities
- Have been treating side effects according to your doctor's instructions but they do not improve

Your experience may vary. Possible serious side effects of RYBREVANT[®] in combination with LAZCLUZE[™], in combination with chemotherapy, or used alone include:



Infusion-related reactions: Infusion-related reactions are common but can be severe or serious and can include life-threatening (anaphylaxis) allergic reaction.

Tell your doctor right away if you experience shortness of breath, difficulty breathing, or wheezing; flushing; chest discomfort; skin rash, hives, or itching; swelling of your eyes, lips, or tongue; nausea or vomiting; fever; stomach cramps; chills; lightheadedness, dizziness, or fainting; numbness of the tongue, lips, cheeks, or gums; or headache.

If you experience an infusion-related reaction: Your treatment team may adjust or pause your infusion dosing and timing to help manage the reaction.



Lung problems: RYBREVANT[®] may cause lung problems that may lead to death. Symptoms of lung problems may be similar to those from your lung cancer.

Tell your doctor right away if you experience any new or worsening lung symptoms, including shortness of breath, cough, or fever.



Blood clots: When RYBREVANT[®] is given in combination with LAZCLUZE[™], blood clots are a serious but common side effect. This can occur in the veins of your legs or lungs.

Tell your doctor right away if you experience swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.

To help prevent blood clots: Your doctor will start you on a medicine for the first 4 months of treatment.

Always tell your care team if you experience side effects, so you can help manage them together

Please read Important Safety Information throughout and on pages 11-14.

Please read full [Prescribing Information](#) for RYBREVANT[®] and full [Prescribing Information](#) for LAZCLUZE[™].

Side Effects (cont'd)



Skin problems: You may experience severe rash.

Tell your doctor right away if you experience blisters, raised, acne-like bumps, peeling, itching, skin pain and sores, dry skin, or redness. If you experience skin problems, your doctor may treat you with a medicine(s) or send you to see a skin doctor.

What you can do: Taking certain steps can help lower your risk of skin-related side effects. Learn about those steps on the next page.



Eye problems: You may experience eye problems. Tell your doctor right away if you experience eye pain, blurred vision, inflammation of the eyelids, changes in vision, dry eyes, itchy eyes, eye redness, excessive tearing, or sensitivity to light. If you experience eye problems, your doctor may send you to see an eye doctor.

What you can do: You should not use contact lenses until your eye symptoms are checked by a doctor.

Harm to your unborn baby

RYBREVANT[®] and LAZCLUZE[™] can harm your unborn baby.

Tell your doctor right away if you become pregnant or think you might be pregnant.

What you can do: If you are able to become pregnant, you should use effective birth control during treatment and for 3 months after your final dose of RYBREVANT[®], and during treatment and for 3 weeks after your last dose of LAZCLUZE[™].

Most common side effects of RYBREVANT[®] in combination with LAZCLUZE[™], in combination with chemotherapy, or used alone:

- Rash
- Infected skin around the nail
- Muscle and joint pain
- Shortness of breath
- Sores in the mouth
- Cough
- Swelling of hands, ankles, feet, face, or all of your body
- Unusual feeling in the skin (such as tingling or crawling feeling)
- Feeling very tired
- Diarrhea
- Constipation
- COVID-19
- Dry skin
- Bleeding
- Decreased appetite
- Itchy skin
- Nausea
- Vomiting
- Changes in certain blood tests

Talk to your doctor about which side effects you may experience with your specific treatment option.

Please read Important Safety Information throughout and on pages 11-14.

Please read full [Prescribing Information](#) for RYBREVANT[®] and full [Prescribing Information](#) for LAZCLUZE[™].

Tips to Help Manage Your Treatment Experience

These steps may lower the chances of skin-related side effects such as rash or infected skin around the nail, or other side effects. Talk to your doctor about what steps are right for you.

Daily, at-home care options to discuss with your care team



Antiseptic cleanser (such as chlorhexidine 4%) to wash your fingernails and toenails once a day.



Mild, ceramide-based moisturizer (such as La Roche-Posay Lipikar or CeraVe[®]*) on your face and body at least once a day.



Limit direct exposure to sunlight, wear protective clothing and sunscreen with SPF \geq 30.



Other medicines

- **Oral and/or topical antibiotics** may be prescribed to reduce risk of skin-related side effects
- **Medicine to lower your risk of blood clots** will be prescribed if you are given RYBREVANT[®] in combination with LAZCLUZE[™]

Make sure to tell your doctor about any other medicines you are taking. Consider using a pill box to help you organize your medicines.

*Talk to your doctor about what is right for you.

†All trademarks are property of their respective owners.

More tips to help throughout treatment



- Consider bathing/showering with warm or cool water (not hot water)
- Use mild soaps and shampoos for sensitive skin



- Use laundry detergents made for sensitive skin and without perfumes
- Wear soft, loose-fitting clothing
- Wear gloves during activities that could cause nail infection (for example, cleaning)



- Eat a balanced diet
- Talk to your doctor about activities that feel right for you
- Seek out support from your family, friends, care team, and/or support groups

IMPORTANT SAFETY INFORMATION (cont'd)

How will I receive RYBREVANT[®]?

- RYBREVANT[®] will be given to you by your healthcare provider by intravenous infusion into your vein.
- Your healthcare provider will decide the time between doses as well as how many treatments you will receive.

Please read Important Safety Information throughout and on pages 11-14.

Please read full [Prescribing Information](#) for RYBREVANT[®] and full [Prescribing Information](#) for LAZCLUZE[™].

Support Communities

Connecting with others during your RYBREVANT[®] journey

Facing lung cancer comes with many challenges, such as discussing the disease and treatment. It can help to find support from other people who are going through similar experiences. There are many groups available to help support you.



BeLUNG Here

An inclusive space created alongside patients, survivors, care partners, advocates, and leaders to provide educational and emotional support for the lung cancer community. It's a space to share stories and find reliable information and solidarity. This website is hosted by Johnson & Johnson.

Visit belunghere.com



LUNGEVITY

A space that helps people diagnosed and living with lung cancer through research, education, and support.


Visit lungevity.org



GO2

This leading group is dedicated to helping save, extend, and improve the lives of those diagnosed with lung cancer.

Visit go2.org



EGFR Resisters

Community dedicated to improving the outcomes for those with EGFR+ lung cancer.

Visit egfrcancer.org



Exon 20 Group

People facing lung cancer, their families, and caregivers are welcome to join this free group.

Visit exon20group.org



Lung Cancer Foundation of America

Their mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.

Visit lcfamerica.org



Support & Savings

Once you and your doctor have decided that a RYBREVANT®-based treatment is right for you, sign up for:

RYBREVANT withMe

Starting a new treatment can be overwhelming and you may still have questions

We are here to help.



Free, 1-on-1 dedicated Care Navigator Support



Cost support options regardless of your insurance type



Additional resources and community connections

Sign up for personalized support throughout your treatment journey now:

Sign up for support
RYBREVANTwithMe.com/signup

OR

Call 833-JNJ-wMe1 (833-565-9631),
Monday through Friday, 8:00 AM–8:00 PM ET

The support and resources provided by **RYBREVANT withMe** are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.



IMPORTANT SAFETY INFORMATION

What is RYBREVANT® (amivantamab-vmjw)?

RYBREVANT® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal epidermal growth factor receptor (EGFR) gene(s):

- in combination with LAZCLUZE™ (lazertinib), a prescription medicine, as a first-line treatment for non-small cell lung cancer (NSCLC)
- in combination with carboplatin and pemetrexed as a second-line treatment for NSCLC in patients whose disease has worsened on or after treatment with an EGFR tyrosine kinase inhibitor (TKI)
- in combination with carboplatin and pemetrexed as a first-line treatment for NSCLC
- alone for the treatment of NSCLC whose disease has worsened on or after platinum-based chemotherapy.

Your healthcare provider will perform a test to make sure that RYBREVANT® or RYBREVANT® in combination with LAZCLUZE™ is right for you.

It is not known if RYBREVANT® or LAZCLUZE™ is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Before you receive RYBREVANT® as a single agent or in combination, tell your healthcare provider about all of your medical conditions, including if you:

- have a history of lung or breathing problems.
- are pregnant or plan to become pregnant. RYBREVANT® and LAZCLUZE™ can harm your unborn baby.

Females who are able to become pregnant:

- o Your healthcare provider should do a pregnancy test before you start treatment with RYBREVANT® or RYBREVANT® in combination with LAZCLUZE™.
- o You should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT®.
- o For patients receiving LAZCLUZE™: You should use effective birth control (contraception) during treatment and for 3 weeks after your last dose of LAZCLUZE™.
- o Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT® or LAZCLUZE™.

Males who have female partners who are able to become pregnant:

- o You should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE™.
- are breastfeeding or plan to breastfeed. It is not known if RYBREVANT® or LAZCLUZE™ passes into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT® or RYBREVANT® in combination with LAZCLUZE™.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

LAZCLUZE™ may affect the way other medicines work, and other medicines may affect how LAZCLUZE™ works.

You should not start or stop any medicine before you talk with your healthcare provider that prescribed LAZCLUZE™.

IMPORTANT SAFETY INFORMATION (cont'd)

How will I receive RYBREVANT®?

- RYBREVANT® will be given to you by your healthcare provider by intravenous infusion into your vein.
- Your healthcare provider will decide the time between doses as well as how many treatments you will receive.
- Your healthcare provider will give you medicines before each dose of RYBREVANT® to help reduce the risk of infusion-related reactions.
- RYBREVANT® may be given in combination with the medicines carboplatin and pemetrexed. If you have any questions about these medicines, ask your healthcare provider.
- If your treatment with RYBREVANT® is given in combination with LAZCLUZE™ (lazertinib), you should take your dose of LAZCLUZE™ by mouth anytime before your infusion with RYBREVANT®.
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

How should I take LAZCLUZE™?

- Take LAZCLUZE™ exactly as your healthcare provider tells you to take it.
- Take LAZCLUZE™ one (1) time each day. On the day RYBREVANT® is also given, take LAZCLUZE™ anytime before receiving the RYBREVANT® infusion.
- You can take LAZCLUZE™ with or without food.
- Swallow LAZCLUZE™ tablets whole. **Do not** crush, cut, or chew the tablets.
- If you miss a dose of LAZCLUZE™ and:
 - o it has been **less than** 12 hours, take the missed dose.
 - o it has been **more than** 12 hours, skip the dose and take your next dose at your regularly scheduled time.
- If you vomit a dose of LAZCLUZE™, do not take an extra dose. Take your next dose at your regularly scheduled time.
- LAZCLUZE™ may be given in combination with other anti-cancer medicines. If you have any questions about these medicines, ask your healthcare provider.

What should I avoid while receiving RYBREVANT® and/or LAZCLUZE™?

RYBREVANT® and RYBREVANT® in combination with LAZCLUZE™ can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment with RYBREVANT® and/or LAZCLUZE™. Wear protective clothing and use sunscreen during treatment with RYBREVANT® and/or LAZCLUZE™.

What are the possible side effects of RYBREVANT® or LAZCLUZE™?

RYBREVANT® and LAZCLUZE™ may cause serious side effects, including:

- **infusion-related reactions.** Infusion-related reactions are common with RYBREVANT® but can be severe or serious and can include life-threatening (anaphylaxis) allergic reaction. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of RYBREVANT®:

- | | | |
|--|---|---|
| o shortness of breath, difficulty breathing, or wheezing | o chills | o nausea or vomiting |
| o chest discomfort | o numbness of the tongue, lips, cheeks, or gums | o stomach cramps |
| o swelling of your eyes, lips, or tongue | o flushing | o lightheadedness, dizziness, or fainting |
| o fever | o skin rash, hives, or itching | o headache |

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of RYBREVANT® or LAZCLUZE™? (cont'd)

- **lung problems.** RYBREVANT® may cause lung problems that may lead to death. LAZCLUZE™ may also cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
- **blood clot problems.** Blood clots are a serious, but common side effect of RYBREVANT®, when given together with LAZCLUZE™, may cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death. Your healthcare provider will start you on medicine to prevent blood clots for the first 4 months of treatment. Tell your healthcare provider right away if you have any signs and symptoms of blood clots, including swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.
- **skin problems.** RYBREVANT® can cause severe rash; including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. LAZCLUZE™ may cause severe rash including redness, raised acne-like bumps, itching, and dry skin. You may use alcohol-free (isopropanol-free, ethanol-free) moisturizing cream to reduce the risk of skin problems. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with RYBREVANT® or LAZCLUZE™. See “What should I avoid while receiving RYBREVANT® and/or LAZCLUZE™?”
- **eye problems.** RYBREVANT® may cause eye problems. LAZCLUZE™ may also cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems which may include:
 - o eye pain
 - o inflammation of eye lids
 - o inflamed cornea (front part of the eye)
 - o dry eyes
 - o eye redness
 - o blurred vision
 - o changes in vision
 - o itchy eyes
 - o excessive tearing
 - o sensitivity to light
 - o new or worsening problems with vision

Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get new or worsening eye problems during treatment with RYBREVANT® or LAZCLUZE™. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.

The most common side effects of RYBREVANT® in combination with LAZCLUZE™ (lazertinib) include:

- rash
- infected skin around the nail
- muscle and joint pain
- sores in the mouth
- swelling of hands, ankles, feet, face, or all of your body
- unusual feeling in the skin (such as tingling or a crawling feeling)
- feeling very tired
- diarrhea
- constipation
- COVID-19
- dry skin
- bleeding
- decreased appetite
- itchy skin
- nausea
- changes in certain blood tests

IMPORTANT SAFETY INFORMATION (cont'd)

The most common side effects of RYBREVANT® when given in combination with carboplatin and pemetrexed include:

- rash
- infected skin around the nail
- feeling very tired
- nausea
- sores in the mouth
- constipation
- swelling of hands, ankles, feet, face, or all of your body
- decreased appetite
- muscle and joint pain
- vomiting
- COVID-19
- changes in certain blood tests

The most common side effects of RYBREVANT® when given alone:

- rash
- infected skin around the nail
- muscle and joint pain
- shortness of breath
- nausea
- feeling very tired
- swelling of hands, ankles, feet, face, or all of your body
- sores in the mouth
- cough
- constipation
- vomiting
- changes in certain blood tests

LAZCLUZE™ may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

Your healthcare provider may temporarily stop, decrease your dose, or completely stop your treatment with RYBREVANT® or LAZCLUZE™ if you have serious side effects.

These are not all of the possible side effects of RYBREVANT® or LAZCLUZE™.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of RYBREVANT®:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

You can ask your healthcare provider or pharmacist for information about RYBREVANT® that is written for health professionals.

General information about the safe and effective use of LAZCLUZE™:

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use LAZCLUZE™ for a condition for which it was not prescribed. Do not give LAZCLUZE™ to other people, even if they have the same symptoms that you have. It may harm them.

You can ask your pharmacist or healthcare provider for information about LAZCLUZE™ that is written for health professionals.

Please read full Prescribing Information for RYBREVANT®.

Please read full Prescribing Information for LAZCLUZE™.

cp-213277v7



Inside, you'll find helpful information about...

Lung Cancer and *EGFR* Mutations
How RYBREVANT® Is Given
Preparing for Treatment
Side Effects
Tips to Help Manage Your Treatment Experience
Support Communities
Support & Savings
Important Safety Information

Learn more about treatment at [RYBREVANT.com](https://www.rybrevant.com)